In many cases, the final therapeutic effect and design goals of the drug may vary. For example, Viagra, developed by Pfizer, was originally designed to treat cardiovascular disease, but it is popular in the market for its completely different efficacy. If pharmaceutical companies can upgrade robotic microscopy and image processing software first, and discover potential new drug targets through experiments, their help in precision pharmaceuticals is unquestionable.
Recursion Pharmaceuticals is a company that uses computer vision technology to process cell images and analyze cell characteristics to assess the post-drug response of disease cells.
They use advanced imaging techniques and artificial intelligence techniques to perform high-throughput cell model experiments, and are committed to detecting thousands of drug candidates in cell models of hundreds of diseases, and finally finding new drugs for different diseases.
According to the arterial network, the company can perform extraordinarily detailed examinations of cells. They use software to measure thousands of characteristics of a cell, such as the size and shape of the nucleus or the distance between different intracellular regions. This sophisticated cell research has not only promoted the medical industry 's awareness, exploration and diagnosis of disease, but also accelerated the transformation of the pharmaceutical model, which greatly benefited patients.
It is not uncommon for companies to use the microscopic image features of cells for drug screening, and Recursion Pharmaceuticals is unique in that it combines machine automation and artificial intelligence technology to parallelize multiple experiments on a large scale. Now, Recursion's lab can perform 30,000 experiments per week. Dr. Chris Gibson, CEO of Recursion, believes that they can conduct hundreds of thousands of experiments per week in the near future.
Studies have shown that about 10% of Americans suffer from rare diseases, most of which stem from a lack of appropriate treatments.
Recursion Pharmaceuticals said it has identified 15 drug candidates for treating rare diseases (those with fewer than 200,000 patients in the United States). Most of these diseases are genetic diseases, and nearly 7,000 rare diseases are currently registered.
Recursion Pharmaceuticals was founded in 2013 in Salt Lake City, Utah, USA. In June 2018, the company received a $20 million credit loan from Square 1 Bank.
Team strength to achieve precise treatment
Dr. Gibson, co-founder and CEO of Recursion Pharmaceuticals, said the company is working hard to achieve precision treatment through collaboration. He firmly believes that the collection and application of high-control, high-organized biological data is at the heart of this goal.
In 2005, Chris Gibson received a Bachelor of Arts in Management Studies and a Bachelor of Science in Bioengineering and Biomedical Technology from Rice University in the United States. In 2009, Chris Gibson began his doctoral studies in bioengineering and medicine at the University of Utah, USA, and received his degree in 2013.
During the study, Dr. Gibson conducted cardiovascular learning in engineering and biology. With the help of the instructor Dr. Dean Li, he established an analytical system to improve the efficiency of new biometric identification, which laid the foundation for the future foundation of Recursion Pharmaceuticals.
In 2013, Dr. Gibson received an Ignite certificate from the Stanford Graduate School of Business. The Stanford University Ignite Certificate is an academic program for entrepreneurs, business and entrepreneurial leaders who learn business-related skills and gain experience in commercializing new businesses.
In addition, Dr. Gibson is also a member of the board of CureHHT. HHT is a hereditary hemorrhagic telangiectasia, a hereditary disease that causes vascular malformations in multiple organs. The CureHHT Foundation is also the only advocacy organization in the world that cares about patients with this disease.
As one of the scientific directors of Recursion Pharmaceuticals, Dr. Yoshua Bengio once said: “Recursion explores millions of high-resolution cell images using deep learning, and their potential and impact are sufficient to promote the breadth of medicine that has never been seen before. Biological excavation."
Dr. Yoshua Bengio is a computer scientist from Quebec, Canada who works on artificial neural networks and deep learning to understand the principles of artificial intelligence. As of September 2017, his research has been cited more than 80,000 times on Google Scholar.
Dr. Bengio received his Ph.D. in computer science from McGill University in Canada in 1991. He was a postdoctoral fellow at the Massachusetts Institute of Technology and AT&T Bell Laboratories. He and the British computer psychologist Geoffrey Hinton, the head of Facebook artificial intelligence laboratory Yann LeCun, together known as the three giants in the field of neural networks.
Since 1993, he has taught at the University of Montreal as a faculty member and has devoted himself to academics in an attempt to train thousands of scientists and engineers. He is also the principal director of the Montreal Institute of Learning Algorithms (MILA) and co-director of the Canadian Institute of Advanced Research's Machine and Brain Learning Program.
In 2017, Dr. Bengio was awarded the Medal of Honor for Canadian Officials and was appointed Academician of the Royal Society of Canada. The Canadian Official Medal of Honor is one of the branches of the Canadian Medal and is awarded to members of society who have made outstanding contributions and services to the Canadian people. In the same year, he also won the Marie-Victorin Quebec Award.
Dr. Bengio is currently the editor of the Journal of Machine Learning Research, the Associate Editor of the Journal of Neurocomputing, the editor of Machine Learning Foundations and Trends, and the Associate Editor of the Journal of Machine Learning and the Journal of IEEE Neural Networks.
Recursion's strategy and cooperation
As co-founder and CEO of Recursion Pharmaceuticals, Dr. Chris Gibson developed the company's business strategy to actively promote innovative pharmaceuticals to achieve business value by continually locating and exploring drugs for patients with rare conditions.
Dr. Gibson said: "The combination of experimental biology and bioinformatics enables us to work more efficiently. At the same time, we are working hard to build more partnerships in the pharmaceutical industry to quickly realize Recursion Pharmaceuticals' business strategy."
In November 2016, Recursion Pharmaceuticals received a $15 million Series A investment in Felicis Venturs, Data Collective, AME Cloud Ventures, Lux Capital, EPIC Ventures and Obvious Ventures.
According to Recursion, the financing will help the company develop "Platform 2.0." On the one hand, the number of rare diseases that researchers study each year can rise from the past dozens to thousands. On the other hand, the new platform can help them understand known drugs, bioactive compounds and those pending pharmaceutical assets in rare diseases.
In October 2017, Recursion Pharmaceuticals received $60 million in Series B investment, with investors including 10 venture capital companies led by Data Collective.
Dr. Gibson said that the round B financing strongly supported the company's continuous advancement in drug positioning. They will use the funds to establish partnerships with large pharmaceutical companies to build treatment channels within the company and expand into emerging therapeutic areas. Dr. Gibson firmly believes: "Recursion will continue to add large, high-dimensional data sets to hundreds of millions of biological interference problems. At the same time, we will be prepared to reliably rely on the trillions of relationships between genes, proteins and chemicals. Bioanalysis."
In November 2017, Recursion Pharmaceuticals announced a formal partnership with Splunk. Recursion uses Splunk's technology to combine bioscience and machine learning to analyze and compare data from thousands of cell culture images and trillions of DNA strands. Recursion Pharmaceuticals aims to achieve the treatment of 100 molecular genetic diseases in 2025.
Rick Fitz, senior vice president of IT at Splunk, said Splunk is proud to help Recursion transform machine data into a cure for genetic diseases. Splunk provides machine learning capabilities in its solutions, fully exploiting the value of data, helping companies solve problems and, in some cases, even saving lives.
How to use AI image technology to discover new drugs and develop treatments?
Although Recursion Pharmaceuticals does not currently have any products on the market, it has 15 treatments for rare diseases in drug development. Co-founder and CEO Dr. Gibson said they found that some potential therapies have been used in clinical trials by other pharmaceutical companies.
“It’s frustrating from a profit perspective, but from a scientific perspective, this confirms the effectiveness of Recursion’s technology,†Dr. Gibson said. “We are able to effectively develop new therapies in the medical field with unique image analysis.â€
Recursion's technology platform uses the latest biotechnology to build hundreds of cell models that mimic rare diseases, taking pictures of these cell models that mimic rare diseases through advanced imaging techniques. Just as rare patients show symptoms, the cell model of rare diseases also exhibits specific characteristics in the cell structure that can be unearthed from photomicrographs.
During the study, Recursion's image analysis software analyzed nearly 1000 cell structural features on micrographs to identify cell characteristics associated with the disease. The software then helps researchers identify treatments that correct the characteristics of these cells in a database of 2,000 known compounds based on the characteristics of these cells.
1. Chemical drugs lead the pharmaceutical industry
According to Recursion Pharmaceuticals, their drug discovery includes localization of reversible complex phenotypic compounds and compounds that remain active in orthogonal disease-specific assays. They used the company's distinctive technology to develop a “smart drug library†with the primary goal of maximizing functional diversity and conducting efficient parallel screening. The screening process is as follows:
- Recursion scans a variety of cell types that generate high-latitude phenotypic signals from the company's parent library, and studies cell movement and toxicity changes through research.
- Establish a “smart drug library†based on the phenotypic/functional diversity maximization feature, including a small number of parent libraries to improve drug screening efficiency. - Screen out “smart drug bank†cells in hundreds of disease models and conduct research and in-depth testing.
- Work with partners to develop a family of cells with high dimensional and toxic signals.
2. Taking drug discovery as the ultimate goal
Recursion Pharmaceuticals conducts objective suppressor gene screening across the genome to provide professional biologic insights for hundreds of disease models for its partners. Recursion's molecular biologists and computer teams combine functional genomics and complex AI techniques in research projects to meet the needs of partners and carry out relevant target identification and validation.
"There are a lot of hype in the current AI space, and many people promise that things won't come true," stressed co-founder and CEO Dr. Gibson. “But there are some real opportunities in the industry to enhance the industry and help it evolve. With the use of computer engines, the industry will grow and improve rapidly.â€
This series of advances is exciting, and Dr. Gibson expects a four-fold increase in the success rate of new clinical drugs at the age of 60. Such success will further advance new business models and create a positive cycle in the pharmaceutical industry.
Medical Instruments And Equipment
Medical Instruments And Equipment,Nucleic Acid Extraction Robo,Nucleic Acid Extraction Instrument,Viral Nucleic Acid Extraction Method,Urine Analyzer
Jilin Sinoscience Technology Co. LTD , https://www.contoryinstruments.com